Krystal Biotech (NASDAQ:KRYS) Shares Gap Up – Should You Buy?

Krystal Biotech, Inc. (NASDAQ:KRYS) gapped up before the market opened on Wednesday . The stock had previously closed at $169.04, but opened at $176.59. Krystal Biotech shares last traded at $166.20, with a volume of 27,542 shares trading hands.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the company. Chardan Capital reaffirmed a “buy” rating and issued a $212.00 target price on shares of Krystal Biotech in a research report on Wednesday. William Blair upgraded shares of Krystal Biotech to a “strong-buy” rating in a research note on Friday, August 30th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Krystal Biotech in a report on Thursday, August 29th. Stifel Nicolaus boosted their price target on Krystal Biotech from $204.00 to $220.00 and gave the company a “buy” rating in a report on Wednesday, September 11th. Finally, Citigroup raised their price objective on Krystal Biotech from $204.00 to $206.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 5th. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $206.67.

Krystal Biotech Stock Up 2.7 %

The company has a market capitalization of $4.63 billion, a P/E ratio of 90.86 and a beta of 0.80. The business has a 50 day simple moving average of $180.46 and a 200-day simple moving average of $185.00.

Krystal Biotech (NASDAQ:KRYS) last posted its earnings results on Monday, November 4th. The company reported $0.91 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.84 by $0.07. The firm had revenue of $83.84 million during the quarter, compared to analyst estimates of $82.94 million. Krystal Biotech had a net margin of 21.68% and a return on equity of 7.54%. Krystal Biotech’s revenue was up 879.9% on a year-over-year basis. During the same period in the previous year, the business posted ($0.67) EPS. Equities analysts forecast that Krystal Biotech, Inc. will post 2.97 EPS for the current fiscal year.

Insider Buying and Selling at Krystal Biotech

In related news, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction that occurred on Friday, December 13th. The stock was sold at an average price of $164.78, for a total transaction of $4,119,500.00. Following the sale, the insider now owns 1,475,882 shares of the company’s stock, valued at $243,195,835.96. The trade was a 1.67 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 14.10% of the stock is owned by company insiders.

Institutional Trading of Krystal Biotech

A number of hedge funds and other institutional investors have recently modified their holdings of KRYS. Key Financial Inc bought a new stake in Krystal Biotech in the second quarter worth about $28,000. Blue Trust Inc. lifted its stake in Krystal Biotech by 2,328.6% during the second quarter. Blue Trust Inc. now owns 170 shares of the company’s stock valued at $30,000 after purchasing an additional 163 shares during the last quarter. Wilmington Savings Fund Society FSB bought a new stake in Krystal Biotech during the third quarter worth approximately $40,000. Values First Advisors Inc. acquired a new position in Krystal Biotech in the third quarter worth approximately $53,000. Finally, Quest Partners LLC bought a new position in shares of Krystal Biotech in the second quarter valued at $71,000. Institutional investors own 86.29% of the company’s stock.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).